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dihydroartemisinin, cytotoxicity and in vivo
efficacy in a Plasmodium berghei mouse model
Catherine Mullié1*, Nicolas Taudon2, Camille Degrouas3, Alexia Jonet1, Aurélie Pascual4, Patrice Agnamey1,5
and Pascal Sonnet1Abstract
Background: As resistance to marketed anti-malarial drugs continues to spread, the need for new molecules active
on Plasmodium falciparum-resistant strains grows. Pure (S) enantiomers of amino-alcohol quinolines previously
displayed a good in vitro anti-malarial activity. Therefore, a more thorough assessment of their potential clinical use
through a rodent model and an in vitro evaluation of their combination with artemisinin was undertaken.
Methods: Screening on a panel of P. falciparum clones with varying resistance profiles and regional origins was
performed for the (S)-pentyl and (S)-heptyl substituted quinoline derivatives, followed by an in vitro assessment of
their combination with dihydroartemisinin (DHA) on the 3D7 clone and an in vivo assay in a mouse model infected
with Plasmodium berghei. Their haemolytic activity was also determined.
Results: A steady anti-malarial activity of the compounds tested was found, whatever the resistance profile or the
regional origin of the strain. (S)-quinoline derivatives were at least three times more potent than mefloquine (MQ),
their structurally close parent. The in vitro combination with DHA yielded an additive or synergic effect for both that
was as good as that of the DHA/MQ combination. In vivo, survival rates were similar to those of MQ for the two
compounds at a lower dose, despite a lack of clearance of the parasite blood stages. A 50% haemolysis was
observed for concentrations at least 1,000-fold higher than the antiplasmodial IC50s.
Conclusions: The results obtained make those two (S)-amino-alcohol quinoline derivatives good candidates for the
development of new artemisinin-based combination therapy (ACT), hopefully with fewer neurologic side effects
than those currently marketed ACT, including MQ.
Keywords: Malaria, Plasmodium falciparum, Plasmodium berghei, in vivo, Anti-malarial activity, Quinoline, Enantiomer,
Dihydroartemisinin, Isobologram, CombinationBackground
The latest figures on the incidence and mortality of mal-
aria show that, despite progress in the implementation of
preventive measures such as insecticide-treated mosquito
nets and intermittent preventive treatments, this parasitic
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unless otherwise stated.and to account for 627,000 deaths in 2012. The death toll
is particularly high in children under five and pregnant
women of the World Health Organization (WHO) African
region [1]. Even though the proportion of Plasmodium
vivax cases rises in certain regions, the vast majority of
malaria cases and deaths are due to Plasmodium falcip-
arum infections [1]. This species has elaborated resistance
mechanisms against almost all anti-malarial drugs avail-
able on the market today [2]. Even artemisinin derivatives
have seen their efficacy challenged in Southeast Asia and,
more recently, in South America [3,4], leading WHO totd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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bination therapy (ACT) as first-line treatment of uncom-
plicated malaria as far back as in 2006 [5]. This
recommendation was reiterated in the 2011 WHO Global
Plan for artemisinin resistance containment [6].
One such ACTcurrently in use is the combination of ar-
temisinin derivatives with mefloquine (MQ). This latter
molecule is marketed as a racemate of its erythro form
(Figure 1) and possesses a long half-life (circa 14 days) that
can be seen as a therapeutic advantage as a lower rate of
relapses has been reported for anti-malarials with long
half-lives [7,8]. However, dose-related neuropsychiatric ad-
verse effects have been reported under MQ use, therefore
contra-indicating it in individuals with a history of epi-
lepsy or psychiatric disease [9,10]. As the (+)-enantiomerFigure 1 Structure of the 4-amino-alcohol quinolines used in this studof MQ was shown to be at least as active as the (−)-en-
antiomer [11,12] and less likely to cause toxicity in the
central nervous system through the blockage of central
adenosine receptors [13], a possible way to circumvent
some of the neurotoxicity of MQ has been envisaged
through the synthesis of a series of enantiomerically pure
MQ amino analogues [14]. Their anti-malarial activity
against P. falciparum W2 and 3D7 strains has also been
documented, showing that (S) enantiomers were more ac-
tive than their (R) counterparts by a factor ranging from 2
to 15, depending on the side chain length [15]. The aim of
this work was therefore to build on these first observa-
tions by choosing the two most effective molecules in the
series, the (S)-pentyl and (S)-heptyl substituted amino-
alcohol quinolines (Figure 1). First, the assessment of theiry.
Table 1 Susceptibility and geographical origin of the
Plasmodium falciparum strains and clones used in this
study




K1 Thailand Ra S
W2 Indochina R S
FCM29 Cameroon R S





HB3 Honduras S R
BRE1 Brazil R R
Dd2 Indochina (from W2
strain)
R R
a:Parasites were considered resistant (R) if their IC50 was higher than 100 nM
for chloroquine and 50 nM for mefloquine.
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from various origins and exhibiting different resistance
profiles to anti-malarial drugs in use, was carried out to
ensure they could be of use against the vast majority of P.
falciparum clones. Then, the two molecules were assessed
in a mouse model of Plasmodium berghei infection to fur-
ther validate their potential as drug candidates, in parallel
with a screening of their potential cytotoxicity. Finally,
their anti-malarial efficacy in combination with one of ar-
temisinin derivatives, dihydroartemisinin (DHA), was
checked to ascertain whether such a combination would
be of relevant clinical use.
Methods
Chemical products
The test drugs included DHA, chloroquine (CQ) diphos-
phate, MQ hydrochloride (Sigma-Aldrich, Saint-Quentin
Fallavier, France) and the 4-amino-alcohol quinolines
represented in Figure 1. The 4-amino-alcohol quinolines
were synthesized following the general procedure de-
scribed by Jonet et al. [14]. Only their (S) enantiomers
were used as they had previously been shown to be more
potent than their (R) analogues [15]. All other chemical
products were purchased from Sigma-Aldrich (Saint-
Quentin-Fallavier, France), unless stated otherwise.
Plasmodium falciparum culture
Parasites were cultivated in A+ human erythrocytes (2%
haematocrit) suspended in RPMI 1640 medium (Invitrogen,
Paisley, UK) supplemented with 10% human serum
(Abcys S A, Paris, France) and buffered with 25 mM
HEPES-25 mM NaHCO3 under controlled atmospheric
conditions (10% O2, 5% CO2, and 85% N2) at 37°C with
95% humidity [16].
Drug sensitivity assay on selected Plasmodium falciparum
clones
The anti-malarial activity of the (S)-pentyl and (S)-heptyl
substituted amino-alcohol quinoline derivatives was
tested against a panel of strains or clones depicted in
Table 1. All strains were twice synchronized with D-
sorbitol 5% (Fluka, Saint Quentin Fallavier, France) before
the assay [17]. CQ and MQ were routinely included as
positive controls as well as negative controls using solvent
(water, dimethyl sulphoxide or methanol, depending on
the drug) .
The 50% inhibitory concentration (IC50) was evalu-
ated using tritiated hypoxanthine [16]. The specific
activity of tritiated hypoxanthine is 1 mCi/mL (Perkin-
Elmer, Courtaboeuf, France). The IC50 values were evalu-
ated by analysing incorporation of tritiated hypoxanthine
according to the concentration by a non-linear regression
analysis processing on dose–response curves (RiaSmart,Packard, Meriden, USA). Results were expressed as geo-
metrical average of IC50.
In vitro combination assay
Plasmodium falciparum parasite strain 3D7 was used for
this experiment. MQ, the (S)-pentyl and (S)-heptyl deriva-
tives were associated with DHA following the fixed-ratio
method of Fivelman et al. [18]. All compounds were solu-
bilized in dimethyl sulphoxide (DMSO) to prepare extem-
poraneous stock solutions. DHA and either the (S)-pentyl,
(S)-heptyl derivative or MQ were then mixed to reach
final ratios of 5:0, 4:1, 3:2, 2:3, 1:4, and 0:5. The mixed
stock solutions were then diluted in supplemented RPMI
medium so as to reach eight times the IC50 previously
determined for the 3D7 strain in the most concentrated
well for the 5:0 mix of each compound. Serial two-fold
dilutions were then carried out in 96-well-plates under a
50 μL final volume to generate a range of six concentra-
tions for each mix. The final concentration of DMSO in
the wells never exceeded 0.02% (v/v). A negative control
with the same amount of DMSO was performed to
check for any potential toxicity. Then, 200 μL of parasit-
ized red blood cells (pRBC) (final parasitaemia of 0.5%
and final haematocrit of 2%) were added. After a
48-hour incubation at 37°C with the drugs, growth
inhibition was assessed and dose–response curves fitted.
The assessment of drug interaction was based on the
calculation of the fractional inhibitory concentrations
(FICs) of the two molecules. The FIC was calculated for
each association by dividing the IC50 of the drug in the
combination by the IC50 of the drug alone. The sum of
these two FICs (∑FICs) was calculated to plot isobolo-
gram curves [18,19] using the software R [20]. ΣFICs <1
denote synergism, ΣFICs ≥1 and <2 denote additive inter-
action, ΣFICs ≥2 and <4 denote slight antagonism, and
Mullié et al. Malaria Journal 2014, 13:407 Page 4 of 8
http://www.malariajournal.com/content/13/1/407ΣFICs ≥4 denote marked antagonism. ΣFICs <0.5 indi-
cate substantial synergism [19].
In vivo assay
The BALB/c female mice used in this assay were four
weeks old and pathogen-free (Charles River Laboratories,
France). They were housed under standard conditions,
with unlimited access to food and water. All experiments
adhered to the French guidelines for animal research and
were approved by the ethical committee of the Institut de
Recherche Biomédicale des Armées - Antenne de Marseille
(Number 2007–02). All efforts were made to minimize ani-
mal suffering.
The P. berghei ANKA line was graciously provided by
Dr Salah Méchéri (Institut Pasteur, Paris, France). Mice
(average body weight 16.7 g) were infected with P. berghei
parasites by intraperitoneal (IP) inoculation of donor
mouse blood diluted in normal saline so as to contain
3.106 infected red blood cells (RBC). Parasitaemia was
then monitored regularly with blood smears. The treat-
ment was started when the parasitaemia of receiver mice
was greater than 1% (Day 0). Five groups of seven mice
were randomly distributed. These groups received a daily
IP dose for five days of either MQ at 9 mg/kg or either the
(S)-pentyl or (S)-heptyl derivative (hydrochloride salts) at
3 or 9 mg/kg under a volume of 100 μL per 20 g of body
weight. A control group (13 mice) received an IP of the
vehicle. Afterwards, the parasitic growth was evaluated
daily by blood smears and mice were monitored for their
survival up to Day 40.
The parasite multiplication rate (PMR) was used to
normalize the activity of the studied compounds on the
parasite growth (treated), to the natural parasite growth
(control) [21].
Survival curves were used to study the likelihood of death
in treated and control mice. They were fitted using Graph-
Pad Prism® software version 5.04 (GraphPad Software Inc,
2012, La Jolla, CA). The survival analysis was performed
according the method of Kaplan-Meier, which determines
the probability of survival when at least one ‘death’ is
recorded [22].
Haemolysis test
The assay was adapted from the protocol described by
Taniyama et al. [23]. Briefly, human RBC were centrifuged
(1,000 g, 10 min), the pellet washed three times with TRIS
buffer (TRIS 10 mmol.L−1, NaCl 150 mmol.L−1, pH 7.4)
and finally diluted at 0.5% (v/v) in the same buffer. Experi-
ments were conducted in triplicate on 96-well plates.
Saponin 1% (m/v) was used as a positive haemolysis
control (100% haemolysis), DMSO and TRIS buffer were
used as negative controls. Fifteen μL of the tested molecule
(concentration range: 120 nmol.L−1 to 500 μmol.L−1) or
control solution were added to 235 μL of the 0.5% (v/v)RBC suspension. Plates were incubated at 37°C for 1 hour
and then centrifuged (1,000 g, 10 min). Then, 100 μL of
supernatant were retrieved from each well for optical dens-
ity measurement at 405 nm. The percentage of haemolytic
activity was calculated using the saponin mean absorbance
at 405 nm as the 100% haemolysis value and the negative
control absorbance at 405 nm as blank. The drug concen-
tration inducing a 50% haemolysis (HC50) was then de-
duced from the dose–response curves.
Statistical analysis
The Pearson’s correlation coefficient between IC50s
values obtained on the various strains for CQ, MQ and
the (S)-pentyl derivative was calculated and the test for
the statistical significance of the obtained value of r
subsequently performed. A log-rank test was performed
to compare the survival and the delay for parasitic
recrudescence curves. A two-way analysis of variance
(ANOVA) on treatment and time parameters was
performed to compare PMR results, using the R soft-
ware [20]. A p-value inferior to 0.05 was considered as
significant.
Results
In vitro anti-malarial activity against selected Plasmodium
falciparum strains/clones
The results obtained for CQ, MQ, the (S)-pentyl, and
(S)-heptyl derivatives are summarized in Table 2. A
one-way ANOVA was first carried out and indicated a
significant difference in IC50s between P. falciparum
clones (p = 1.7 10−8) for MQ. Post-ANOVA tests con-
firmed the differences in IC50s between clones K1 and
FCM29 (p = 0.02), FCM29 and 3D7 (p = 4.48 10−4),
3D7 and Dd2 (p = 0.0173). A two-way ANOVA, taking
into account both the strain and the molecule tested,
pointed towards a significant difference between
groups (p = 5.45 10−14).
These strains were selected to evaluate the efficacy of
the (S)-pentyl substituted amino-alcohol quinoline
against a variety of resistance profiles both to CQ and
MQ and, to a lesser extent, the efficiency of the (S)-
heptyl. The clones were also selected to allow for a
variety of geographical origins. As similar results were
obtained for both derivatives on the first two strains
against which the molecules were tested (3D7 and W2),
only the (S)-pentyl derivate was thereafter tested on the
other strains. The IC50s obtained with this compound
ranged from 3.7 nmol.L−1 (FCM29 clone) to 13.9 nmol.
L−1 (HB3 clone) and were constantly lower than those
observed for CQ and, more interestingly, than those for
MQ, their structurally close parent (Table 2). These low
IC50s were retained whatever the resistance profile
exhibited by the strains/clones or their geographical
origin. The correlations between the CQ and (S)-pentyl
Table 2 IC50s expressed as average (CV%) for CQ, MQ, (S)-pentyl and (S)-heptyl derivatives on the selected Plasmodium
falciparum strains and clones
IC50 (nmol L
−1) Ratio
Strain/Clone CQ MQ S-pentyl S-heptyl MQ/(S)-pentyl CQ/(S)-pentyl
K1 164 (35.1) 14.3 (28.0) 4.1 (21.0) NDa 3.5 40.0
W2 572 (19.5) 26.5 (9.2) 7.0 (8.9) 9.4 (9.7) 3.8 81.7
FCM29 738 (7.2) 24.5 (10.1) 3.7 (10.5) ND 6.6 199.6
3D7 21.2 (13.7) 67.0 (5.89) 12.8 (3.1) 14.5 (8.5) 5.3 1.7
BRE1 265 (33.0) 72.3 (10.4) 11.7 (6.9) ND 6.2 22.6
Dd2 169 (20.4) 84.7 (7.8) 5.5 (19.3) ND 15.9 30.7
HB3 13.8 (20.5) 98.7 (9.8) 13.9 (7.4) ND 7.1 1.0
a:not determined.
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tically significant (p = 0.144 and p = 0.0659, respect-
ively). However, CQ and (S)-pentyl IC50s tended to
display a negative correlation while MQ and (S)-pentyl
IC50s tended to be positively correlated (r = −0.612 andFigure 2 Isobolograms obtained on the Plasmodium falciparum 3D7 c
derivative, DHA/S-heptyl derivative. Coloured zones represent synergy, a
dashed red and solid red, respectively.r = 0.724, respectively). Nevertheless, the calculated
MQ/(S)-pentyl IC50s ratios varied from 3.5 to 15.9, de-
pending on the strains, giving a clue to an at least par-
tially different mechanism of action for this compound
as compared to MQ.lone for the following combinations: DHA/MQ, DHA/S-pentyl
dditivity, indifference and antagonism for solid green, dashed green,
Figure 3 Parasite multiplication rates of Plasmodium berghei
ANKA expressed as mean ± standard error.
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Figure 2 displays the isobolograms resulting from the plot-
ting of ΣFICs obtained on P. falciparum 3D7 for the fixed
ratios of MQ/DHA, (S)-pentyl/DHA and (S)-heptyl/DHA.
The results observed for the MQ/DHA combination are
in the range of those previously reported for example by
Gupta et al. [24] with a ΣFICs of 0.93 or by Kerschbaumer
et al. [25] with a ΣFICs of 0.5991 at the IC50.
Similar values were obtained for the substituted amino-
alcohol quinolines as only the (S)-pentyl/DHA associ-
ation for which the 3:2 and 2:3 ratios exhibited a ΣFIC
superior to 1, as well as the 3:2 ratio for the (S)-heptyl/
DHA combination. Otherwise, ΣFICs for the combina-
tions tested fell between 0.5 and 1, similarly to the ΣFICs
obtained for the MQ/DHA combination, denoting a
synergistic effect at least as good as that of MQ for the
new compounds tested.
In vivo anti-malarial activity
Parasite multiplication rate (PMR)
After inoculation, all mice showed positive parasitaemia.
When drug administrations were started, an averageTable 3 P-values obtained for post-ANOVA two-by-two comp
(S)-pentyl
3 mg kg−1
(S)-pentyl 9 mg kg−1 0.00132a
(S)-heptyl 3 mg kg−1 0.0749
9 mg kg−1 5.64 10−5
MQ 9 mg kg−1 9.47 10−6
a:statistically significant values are indicated in bold characters.parasitaemia of 5.2% was observed (95% confidence inter-
val, 1.5-6.0%). As can be seen on Figure 3, at the dose of
9 mg kg−1, MQ enabled a clearance of blood parasites
within 72 hours. This clearance time is consistent with
clinical results obtained in children after a single oral
dose of MQ at 25 mg kg−1 [26] and in adults after a
single 1,000 mg oral dose of MQ [27], although it has to
be specified that the administration route was different in
these clinical studies as compared to the implemented
animal model. The (S)-pentyl and (S)-heptyl derivatives
at 3 mg kg−1 did not prevent the parasite multiplication
within infected animals. However, at 9 mg kg−1, a
decrease in the PMR was observed for both compounds,
although the clearance of parasites could not be achieved.
The statistical analysis (Table 3) indicated the PMR was
significantly lower in the MQ group as compared to all of
the others. Additionally, a dose effect was observed as
the 9 mg kg−1 of both amino-alcohol quinoline deriva-
tives was significantly more efficient in reducing the
PMR than their 3 mg kg−1 dose (Table 3). No significant
difference was found between the (S)-pentyl and (S)-hep-
tyl efficiencies at either 3 or 9 mg kg−1.
Survival curves
The fitted survival curves are presented in Figure 4. The
overall test of Mantel Cox emphasized a statistically sig-
nificant difference between the groups (p <0.0001). The
results of the subsequent two-by-two analysis are re-
ported in Table 4. By Day 17, all mice in the control
group had died while in treated groups, mice survived
significantly longer, whatever the treatment (Table 4).
When the survival in the MQ arm is compared to the
ones in arms treated with the amino-alcohol quinoline
derivatives, a significant difference was only found for the
(S)-pentyl at 9 mg kg−1 arm for which the survival was
lower. For the (S)-heptyl derivative at the same dose, the
difference was not significant. One would have expected
the survival curves to be better at the higher concentra-
tion tested for amino-alcohol quinoline derivatives.
However, some toxicity might explain the difference in
survival witnessed in vivo for the 9 mg kg−1 dose. Inter-
estingly, for either derivative at 3 mg kg−1, the survival
was as good as the one witnessed for MQ, even though
the PMR failed to be reduced at the same concentration.arisons on parasite multiplication rates
(S)-heptyl
9 mg kg−1 3 mg kg−1 9 mg kg−1
0.295
0.0810 0.0348
1.62 10−7 5.02 10−5 3.49 10−7
Figure 4 Survival curves of the BALB/c female mice infected
with Plasmodium berghei ANKA.
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and above witnessed on the various P. falciparum clones
(Table 2) is, therefore, corroborated in vivo as similar sur-
vival rates were obtained with a dose of derivatives that was
one third of the MQ one. However, the PMR did not de-
cline in similar ways with the tested compounds and MQ.
The failure to clear the parasites from blood might be due
to a slower effect of these molecules, as compared to the
one of MQ. Also, the activity of these compounds on se-
questered forms, which cannot be investigated by the PMR
evaluation, might explain a gain of survival time not associ-
ated with a PMR decrease for mice receiving the dose of
3 mg kg−1. Along with possible differences in pharmacokin-
etics, these hypotheses could explain the similar survival
rates observed with MQ derivatives, even though the clear-
ance of parasites as measured by the PMR technique was
not achieved on Day 5 with these compounds.
Haemolysis test
As a preliminary way to assess the potential cytotoxicity of
the (S)-pentyl and (S)-heptyl derivatives, as they appeared
to act on the erythrocytic stage of the parasite cycle, their
haemolytic activity was evaluated. The HC50 determined
for the (S)-pentyl and (S)-heptyl derivatives were of
302 μmol L−1 (95% confidence interval [301.0-302.8]) and
261 μmol L−1 (95% confidence interval [235.1-287.9]),
respectively. Meanwhile, under the same experimental
conditions, MQ displayed an HC50 of 203 μmol L
−1 (95%Table 4 P-values for differences in survival curves according t
(S)-pentyl
3 mg kg−1 9 mg kg
Control 0.0059a 0.0017
(S)-pentyl 3 mg kg−1 0.5691
9 mg kg−1
(S)-heptyl 3 mg kg−1
9 mg kg−1
a:statistically significant values are indicated in bold characters.confidence interval [197.0-210.0]). Therefore, the least
favourable HC50/IC50 ratios calculated for MQ, the (S)-
pentyl and (S)-heptyl derivatives would be of 2,057, 21,726
and 18,000, respectively. As regards the haemolytic activ-
ity, the (S)-amino-alcohol quinoline derivatives would
then have a ten-fold higher safety margin than their MQ
parent. An additional point can be made on the safety of
use for these products as, in a previous report, the cyto-
toxicity of MQ and its (R)-amino-alcohol derivatives was
evaluated on hepatocellular carcinoma HepG2 cells using
the MTT assay [28]. Inhibitory concentrations 50, in this
case defined as concentrations of products leaving 50% of
viable cells as compared to the control, were calculated
after a 24-hour incubation with MQ or the amino-alcohol
derivatives. The (R)-heptyl derivative IC50 value was found
to be of 16.6 μg mL−1 (39.3 μmol L−1). MQ gave an IC50
value of 11 μg mL−1 (26.5 μmol L−1). The (S)-heptyl de-
rivative, but not the (S)-pentyl one, was tested at the same
time and yielded an IC50 of 26.2 μg mL
−1/66.5 μmol L−1
(95% confidence interval [19.9-32.6 μg mL−1]/[50.5-
82.7 μmol L−1]). The safety indexes of MQ and the (S)-
heptyl derivative calculated on this model were of 268 and
5,752, respectively. Based on these results, the enantio-
merically pure amino-alcohol quinoline derivatives would
be at least as safe to use as MQ.
Conclusion
The (S)-pentyl and (S)-heptyl amino-alcohol quinoline
derivatives studied in this work displayed a steady activity
against a panel of P. falciparum clones with varying
resistance profiles to CQ and MQ and from different re-
gional origins. Three major points in favour of a continu-
ing development of these compounds in preclinical
studies were (i) their in vitro combination with DHA that
allowed for addition of the effects or synergy, depending
on the ratios tested, and displayed an anti-malarial activ-
ity as good as that of the DHA/MQ combination; (ii)
in vivo survival rates as good as those of MQ, in a
mouse-model of P. berghei ANKA infection; and, (iii)
HC50s at least 1,000-fold higher than their antiplasmodial
IC50s, pointing towards a rather safe use as compared to
MQ. Taken together, and even though the precise mech-
anism of action of these compounds remains to beo the treatment received
(S)-heptyl Mefloquine
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http://www.malariajournal.com/content/13/1/407elucidated, the results obtained here make those two (S)-
amino-alcohol quinoline derivatives good candidates for
the development of new ACT, hopefully with fewer
neurologic side effects than those currently marketed
ACT including MQ, their structurally close parent.
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